Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 9/2020

Open Access 01-09-2020 | Obesity | Genetics (AP Morris, Section Editor)

Bariatric Surgery for Monogenic Non-syndromic and Syndromic Obesity Disorders

Authors: Niels Vos, Sabrina M. Oussaada, Mellody I. Cooiman, Lotte Kleinendorst, Kasper W. ter Horst, Eric J. Hazebroek, Johannes A. Romijn, Mireille J. Serlie, Marcel M. A. M. Mannens, Mieke M. van Haelst

Published in: Current Diabetes Reports | Issue 9/2020

Login to get access

Abstract

Purpose of Review

The global prevalence of obesity has increased rapidly over the last decades, posing a severe threat to human health. Currently, bariatric surgery is the most effective therapy for patients with morbid obesity. It is unknown whether this treatment is also suitable for patients with obesity due to a confirmed genetic defect (genetic obesity disorders). Therefore, this review aims to elucidate the role of bariatric surgery in the treatment of genetic obesity.

Recent Findings

In monogenic non-syndromic obesity, an underlying genetic defect seems to be the most important factor determining the efficacy of bariatric surgery. In syndromic obesity, bariatric surgery result data are scarce, and even though some promising follow-up results have been reported, caution is required as patients with more severe behavioral and developmental disorders might have poorer outcomes.

Summary

There is limited evidence in support of bariatric surgery as a treatment option for genetic obesity disorders; hence, no strong statements can be made regarding the efficacy and safety of these procedures for these patients. However, considering that patients with genetic obesity often present with life-threatening obesity-related comorbidities, we believe that bariatric surgery could be considered a last-resort treatment option in selected patients.
Appendix
Available only for authorised users
Literature
1.
(WHO) WHO. The top 10 causes of death. 2018.
2.
3.
Oussaada SM, van Galen KA, Cooiman MI, Kleinendorst L, Hazebroek EJ, van Haelst MM, et al. The pathogenesis of obesity. Metabolism. 2019;92:26–36.
4.
Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18(7):715–23.PubMed
5.
Kleinendorst L, Massink MPG, Cooiman MI, Savas M, van der Baan-Slootweg OH, Roelants RJ, et al. Genetic obesity: next-generation sequencing results of 1230 patients with obesity. J Med Genet. 2018;55(9):578–86.
6.
Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet. 2005;6(3):221–34.PubMed
7.
Nordang GBN, Busk OL, Tveten K, Hanevik HI, Fell AKM, Hjelmesaeth J, et al. Next-generation sequencing of the monogenic obesity genes LEP, LEPR, MC4R, PCSK1 and POMC in a Norwegian cohort of patients with morbid obesity and normal weight controls. Mol Genet Metab. 2017;121(1):51–6.PubMed
8.
Saeed S, Bonnefond A, Manzoor J, Shabbir F, Ayesha H, Philippe J, et al. Genetic variants in LEP, LEPR, and MC4R explain 30% of severe obesity in children from a consanguineous population. Obesity (Silver Spring, Md). 2015;23(8):1687–95.
9.
Akinci A, Turkkahraman D, Tekedereli I, Ozer L, Evren B, Sahin I, et al. Novel mutations in obesity-related genes in Turkish children with non-syndromic early onset severe obesity: a multicentre study. J Clin Res Pediatr Endocrinol. 2019;11(4):341–9.PubMedPubMedCentral
10.
11.
Rohde K, Keller M, la Cour PL, Bluher M, Kovacs P, Bottcher Y. Genetics and epigenetics in obesity. Metabolism. 2019;92:37–50.PubMed
12.
Poirier P, Cornier MA, Mazzone T, Stiles S, Cummings S, Klein S, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123(15):1683–701.
13.
Aarts EO, Dogan K, Koehestanie P, Aufenacker TJ, Janssen IM, Berends FJ. Long-term results after laparoscopic adjustable gastric banding: a mean fourteen year follow-up study. Surg Obes Relat Dis. 2014;10(4):633–40.PubMed
14.
Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740–8.
15.
Ramon JM, Salvans S, Crous X, Puig S, Goday A, Benaiges D, et al. Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose and gut hormones: a prospective randomised trial. J Gastrointest Surg. 2012;16(6):1116–22.PubMed
16.
Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, et al. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obes Surg. 2014;24(2):241–52.
17.
Inge TH, Coley RY, Bazzano LA, Xanthakos SA, McTigue K, Arterburn D, et al. Comparative effectiveness of bariatric procedures among adolescents: the PCORnet bariatric study. Surg Obes Relat Dis. 2018;14(9):1374–86.
18.
Crowley VE. Overview of human obesity and central mechanisms regulating energy homeostasis. Ann Clin Biochem. 2008;45(Pt 3):245–55.PubMed
19.
Farooqi IS, O'Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. Nat Clin Pract Endocrinol Metab. 2008;4(10):569–77.PubMed
20.
Farooqi S, O'Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27(7):710–8.PubMed
21.
22.
Kleinendorst L Chapter 5 - Molecular basis of obesity disorders. Clinical molecular medicine: principles and practice. In: Van Haelst MM, editor.: Elsevier; 2020. p. 80.
23.
Doulla M, McIntyre AD, Hegele RA, Gallego PH. A novel MC4R mutation associated with childhood-onset obesity: a case report. Paediatr Child Health. 2014;19(10):515–8.PubMedPubMedCentral
24.
Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, Butler G, et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest. 2000;106(2):271–9.PubMedPubMedCentral
25.
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085–95.PubMed
26.
Potoczna N, Branson R, Kral JG, Piec G, Steffen R, Ricklin T, et al. Gene variants and binge eating as predictors of comorbidity and outcome of treatment in severe obesity. J Gastrointest Surg. 2004;8(8):971–81 discussion 81-2.PubMed
27.
Valette M, Poitou C, Le Beyec J, Bouillot JL, Clement K, Czernichow S. Melanocortin-4 receptor mutations and polymorphisms do not affect weight loss after bariatric surgery. PLoS One. 2012;7(11):e48221.PubMedPubMedCentral
28.
Aslan IR, Campos GM, Calton MA, Evans DS, Merriman RB, Vaisse C. Weight loss after Roux-en-Y gastric bypass in obese patients heterozygous for MC4R mutations. Obes Surg. 2011;21(7):930–4.PubMed
29.
Hatoum IJ, Stylopoulos N, Vanhoose AM, Boyd KL, Yin DP, Ellacott KL, et al. Melanocortin-4 receptor signaling is required for weight loss after gastric bypass surgery. J Clin Endocrinol Metab. 2012;97(6):E1023–31.PubMedPubMedCentral
30.
Censani M, Conroy R, Deng L, Oberfield SE, McMahon DJ, Zitsman JL, et al. Weight loss after bariatric surgery in morbidly obese adolescents with MC4R mutations. Obesity (Silver Spring, Md). 2014;22(1):225–31.
31.
Mul JD, Begg DP, Alsters SI, van Haaften G, Duran KJ, D'Alessio DA, et al. Effect of vertical sleeve gastrectomy in melanocortin receptor 4-deficient rats. Am J Physiol Endocrinol Metab. 2012;303(1):E103–10.PubMedPubMedCentral
32.
Moore BS, Mirshahi UL, Yost EA, Stepanchick AN, Bedrin MD, Styer AM, et al. Long-term weight-loss in gastric bypass patients carrying melanocortin 4 receptor variants. PLoS One. 2014;9(4):e93629.
33.
Elkhenini HF, New JP, Syed AA. Five-year outcome of bariatric surgery in a patient with melanocortin-4 receptor mutation. Clin Obes. 2014;4(2):121–4.PubMed
34.
• Jelin EB, Daggag H, Speer AL, Hameed N, Lessan N, Barakat M, et al. Melanocortin-4 receptor signaling is not required for short-term weight loss after sleeve gastrectomy in pediatric patients. Int J Obes. 2016;40(3):550–3. Paediatric patients with homozygous. MC4R. mutations show initial short-term weight loss. At long term, there was weight regain in one patient.
35.
• Bonnefond A, Keller R, Meyre D, Stutzmann F, Thuillier D, Stefanov DG, et al. Eating behavior, low-frequency functional mutations in the melanocortin-4 receptor (MC4R) gene, and outcomes of bariatric operations: a 6-year prospective study. Diabetes Care. 2016;39(8):1384–92. Carriers of. MC4R. variants had poorer outcomes after bariatric surgery. The described variants are not all pathogenic. It is therefore hard to draw firm conclusions.PubMed
36.
•• Cooiman MI, Kleinendorst L, Aarts EO, Janssen IMC, van Amstel HKP, Blakemore AI, et al. Genetic obesity and bariatric surgery outcome in 1014 patients with morbid obesity. Obes Surg. 2020;30(2):470–7. Various genetic defects are described. RYGB is more effective than SG in patients with an. MC4R. mutation. No significant differences in bariatric surgery outcomes between patients with. PCSK1, POMC, and. SIM1. mutations and non-carriers.PubMed
37.
Kleinendorst L, Abawi O, van der Kamp HJ, Alders M, Meijers-Heijboer HEJ, van Rossum EFC, et al. Leptin receptor deficiency: a systematic literature review and prevalence estimation based on population genetics. Eur J Endocrinol. 2020;182(1):47–56.
38.
Nizard J, Dommergues M, Clément K. Pregnancy in a woman with a leptin-receptor mutation. N Engl J Med. 2012;366(11):1064–5.PubMed
39.
Huvenne H, Le Beyec J, Pepin D, Alili R, Kherchiche PP, Jeannic E, et al. Seven novel deleterious LEPR mutations found in early-onset obesity: a DeltaExon6-8 shared by subjects from Reunion Island, France, suggests a founder effect. J Clin Endocrinol Metab. 2015;100(5):E757–66.PubMed
40.
•• Nunziata A, Funcke JB, Borck G, von Schnurbein J, Brandt S, Lennerz B, et al. Functional and phenotypic characteristics of human leptin receptor mutations. J Endocr Soc. 2019;3(1):27–41. This review provides an overview of what is known of the outcomes of bariatric surgery in patients with biallelic. LEPR. mutations. Gender-related differences are seen, with long-lasting weight loss in males (n=3), but not in females (n=3).PubMed
41.
Le Beyec J, Cugnet-Anceau C, Pepin D, Alili R, Cotillard A, Lacorte JM, et al. Homozygous leptin receptor mutation due to uniparental disomy of chromosome 1: response to bariatric surgery. J Clin Endocrinol Metab. 2013;98(2):E397–402.PubMed
42.
Dehghani M, Mehrjardi M, Dilaver N, Tajamolian M, Enayati S, Ebrahimi P, et al. Potential role of gender specific effect of leptin receptor deficiency in an extended consanguineous family with severe early-onset obesity. Eur J Med Genet. 2018;61:465–7.PubMed
43.
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155–7.PubMed
44.
Millington GW. Proopiomelanocortin (POMC): the cutaneous roles of its melanocortin products and receptors. Clin Exp Dermatol. 2006;31(3):407–12.PubMed
45.
Mountjoy KG, Caron A, Hubbard K, Shome A, Grey AC, Sun B, et al. Desacetyl-alpha-melanocyte stimulating hormone and alpha-melanocyte stimulating hormone are required to regulate energy balance. Mol Metab. 2018;9:207–16.
46.
Dubern B, Lubrano-Berthelier C, Mencarelli M, Ersoy B, Frelut ML, Bougle D, et al. Mutational analysis of the pro-opiomelanocortin gene in French obese children led to the identification of a novel deleterious heterozygous mutation located in the alpha-melanocyte stimulating hormone domain. Pediatr Res. 2008;63(2):211–6.PubMed
47.
Kublaoui BM, Holder JL Jr, Gemelli T, Zinn AR. Sim1 haploinsufficiency impairs melanocortin-mediated anorexia and activation of paraventricular nucleus neurons. Mol Endocrinol. 2006;20(10):2483–92.PubMed
48.
Blackburn PR, Sullivan AE, Gerassimou AG, Kleinendorst L, Bersten DC, Cooiman M, et al. Functional analysis of the SIM1 variant p.G715V in 2 patients with obesity. J Clin Endocrinol Metab. 2020;105(1).
49.
50.
Stijnen P, Ramos-Molina B, O'Rahilly S, Creemers JW. PCSK1 mutations and human endocrinopathies: from obesity to gastrointestinal disorders. Endocr Rev. 2016;37(4):347–71.PubMed
51.
Kaur Y, de Souza RJ, Gibson WT, Meyre D. A systematic review of genetic syndromes with obesity. Obes Rev. 2017;18(6):603–34.PubMed
52.
53.
Chen C, Visootsak J, Dills S, Graham JM Jr. Prader-Willi syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila). 2007;46(7):580–91.
54.
Miller JL, Lynn CH, Driscoll DC, Goldstone AP, Gold JA, Kimonis V, et al. Nutritional phases in Prader-Willi syndrome. Am J Med Genet A. 2011;155a(5):1040–9.PubMedPubMedCentral
55.
Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews(®). Seattle (WA): University of Washington, Seattle Copyright © 1993–2020, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993
56.
Tauber M, Diene G, Molinas C, Hebert M. Review of 64 cases of death in children with Prader-Willi syndrome (PWS). Am J Med Genet A. 2008;146A(7):881–7.PubMed
57.
58.
Lima VP, Emerich DR, Mesquita ML, Paternez AC, Carreiro LR, Pina Neto JM, et al. Nutritional intervention with hypocaloric diet for weight control in children and adolescents with Prader-Willi syndrome. Eat Behav. 2016;21:189–92.PubMed
59.
le Roux CW, Heneghan HM. Bariatric surgery for obesity. Med Clin N Am. 2018;102(1):165–82.PubMed
60.
Scheimann AO, Butler MG, Gourash L, Cuffari C, Klish W. Critical analysis of bariatric procedures in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2008;46(1):80–3.PubMedPubMedCentral
61.
• Alqahtani AR, Elahmedi MO, Al Qahtani AR, Lee J, Butler MG. Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study. Surg Obes Relat Dis. 2016;12(1):100–10. This study describes the effect of SG in children with PWS and shows similar BMI loss up to 3 years after surgery, compared with controls.PubMed
62.
•• Cazzo E, Gestic MA, Utrini MP, Chaim FDM, Candido EC, Jarolavsky L, et al. Bariatric surgery in individuals with severe cognitive impairment: report of two cases. Sao Paulo Med J. 2018;136(1):84–8. One child with PWS responded well to BPD (55% excess weight loss after 1 year).PubMed
63.
•• Martinelli V, Chiappedi M, Pellegrino E, Zugnoni M, Caccialanza R, Muggia C, et al. Laparoscopic sleeve gastrectomy in an adolescent with Prader-Willi syndrome: psychosocial implications. Nutrition. 2019;61:67–9. One child with PWS responded well to SG (29.2% excess weight loss after 6 months).PubMed
64.
• Michalik M, Frask A, Lech P, Zdrojewski M, Doboszynska A. The usefulness of biliopancreatic diversion/Scopinaro operation in treatment of patients with Prader-Willi syndrome. Wideochir Inne Tech Maloinwazyjne. 2015;10(2):324–7. Two patients with PWS responded well to BPD (25 to 43% excess weight loss after 18 and 6 months respectively).PubMedPubMedCentral
65.
Stevenson DA, Heinemann J, Angulo M, Butler MG, Loker J, Rupe N, et al. Gastric rupture and necrosis in Prader-Willi syndrome. J Pediatr Gastroenterol Nutr. 2007;45(2):272–4.
66.
Forsythe E, Beales PL. Bardet-Biedl Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA)1993.
67.
Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet-Biedl syndrome-now and in the future. Front Pediatr. 2018;6:23.PubMedPubMedCentral
68.
Daskalakis M, Till H, Kiess W, Weiner RA. Roux-en-Y gastric bypass in an adolescent patient with Bardet-Biedl syndrome, a monogenic obesity disorder. Obes Surg. 2010;20(1):121–5.PubMed
69.
Uday S, Ali M, Azam W, Barrett T. Effect of dietetic management on weight in children with Bardet-Biedl syndrome. Endocrine Abstracts 2015.
70.
•• Boscolo M, Fery F, Cnop M. Beneficial outcomes of sleeve gastrectomy in a morbidly obese patient with Bardet-Biedl Syndrome. J Endocr Soc. 2017;1(4):317–22. One patient with BBS, good response to SG (32.6% total weight loss after 3 years).PubMedPubMedCentral
71.
•• Ates U, Ergun E, Gollu G, Sozduyar S, Can OS, Yagmurlu A. Pediatric laparoscopic sleeve gastrectomy in Turkey: short-term results. Pediatr Int. 2018;60(5):461–6. One patient with BBS, good response to SG (28% total weight loss after 1 year).PubMed
72.
Albright F, Forbes AP, Henneman PH. Pseudo-pseudohypoparathyroidism. Trans Assoc Am Phys. 1952;65:337–50.PubMed
73.
Patten JL, Johns DR, Valle D, Eil C, Gruppuso PA, Steele G, et al. Mutation in the gene encoding the stimulatory G protein of adenylate cyclase in Albright’s hereditary osteodystrophy. N Engl J Med. 1990;322(20):1412–9.
74.
Weinstein LS, Yu S, Warner DR, Liu J. Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev. 2001;22(5):675–705.PubMed
75.
Ferrario C, Gastaldi G, Portmann L, Giusti V. Bariatric surgery in an obese patient with Albright hereditary osteodystrophy: a case report. J Med Case Rep. 2013;7:111.PubMedPubMedCentral
76.
Beamish AJ, Reinehr T. Should bariatric surgery be performed in adolescents? Eur J Endocrinol. 2017;176(4):D1–d15.PubMed
77.
Kumar S, Kelly AS. Review of childhood obesity: from epidemiology, etiology, and comorbidities to clinical assessment and treatment. Mayo Clin Proc. 2017;92(2):251–65.PubMed
Metadata
Title
Bariatric Surgery for Monogenic Non-syndromic and Syndromic Obesity Disorders
Authors
Niels Vos
Sabrina M. Oussaada
Mellody I. Cooiman
Lotte Kleinendorst
Kasper W. ter Horst
Eric J. Hazebroek
Johannes A. Romijn
Mireille J. Serlie
Marcel M. A. M. Mannens
Mieke M. van Haelst
Publication date
01-09-2020
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 9/2020
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-020-01327-7

Other articles of this Issue 9/2020

Current Diabetes Reports 9/2020 Go to the issue

Pathogenesis of Type 1 Diabetes (A Pugliese and SJ Richardson, Section Editors)

Lipidomic Abnormalities During the Pathogenesis of Type 1 Diabetes: a Quantitative Review

Obesity (KM Gadde and P Singh, Section Editors)

Endocrine Mechanisms Connecting Exercise to Brown Adipose Tissue Metabolism: a Human Perspective

Pathogenesis of Type 1 Diabetes (A Pugliese and S Richardson, Section Editors)

miRNA Regulation of T Cells in Islet Autoimmunity and Type 1 Diabetes

Other Forms of Diabetes and Its Complications (JJ Nolan and H Thabit, Section Editors)

Early Onset of Autoimmune Diabetes in Children with Down Syndrome—Two Separate Aetiologies or an Immune System Pre-Programmed for Autoimmunity?

Genetics (AP Morris, Section Editor)

New Insights into the Genetics of Latent Autoimmune Diabetes in Adults

Pathogenesis of Type 2 Diabetes and Insulin Resistance (ME Patti, Section Editor)

Type 2 Diabetes in Youth: the Role of Early Life Exposures

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits